Clinical-stage immunotherapy firm ImmunityBio (NASDAQ: IBRX), completes accrual of the first two phases of a national trial assessing its Nant Cancer Vaccine (NCV) in participants with Lynch syndrome.
Utilising a tri-valent Adenovirus (Tri-Ad5) combined with IL-15 superagonist N-803, the trial aims to prevent colon and other cancers.
Lynch syndrome, associated with a genetic mutation, elevates cancer risks.
ImmunityBio's study progresses to the randomised controlled phase, aiming to enroll up to 186 individuals.
The vaccine targets cancer-specific proteins to activate natural killer and T cells for potential cancer prevention. ImmunityBio's investigational Tri-Ad5 Vaccines and N-803 continue to be studied for safety and efficacy, with a focus on preventing colorectal and other cancers associated with Lynch syndrome.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member